Genmab licenses agiogenesis targets from Bionomics
Under the terms of the deal, Bionomics will receive an upfront fee and additional fees upon the first target achieving specified preclinical and clinical milestones. Bionomics will also receive milestone payments and royalties on product sales for each product that reaches the market.
Bionomics will retain rights to a large number of additional proprietary proteins it has discovered in its angiogenesis program, including, BNO69. Bionomics is continuing to develop BNO69 as a target for small molecule therapeutics for the treatment of breast cancer.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.